CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc.
Your view on CNSP
Overview
What the company does, where it operates, and who runs it.
About CNS Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Michael Climaco
- Headquarters
- 2100 West Loop South, Houston, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Michael Climaco
- Headquarters
- 2100 West Loop South, Houston, TX, US
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme.
It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D.
Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for CNS Pharmaceuticals, Inc., and the rating behind it. CNSP last traded at $5.84; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for CNS Pharmaceuticals, Inc.. Starting points for CNS Pharmaceuticals, Inc.: EPS -$2.44, beta 1.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for CNS Pharmaceuticals, Inc.. CNS Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for CNS Pharmaceuticals, Inc.. Trailing twelve-month EPS for CNS Pharmaceuticals, Inc. stands at -$2.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for CNS Pharmaceuticals, Inc.. CNS Pharmaceuticals, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
CNS Pharmaceuticals, Inc. valued side by side against its closest peers. CNS Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold CNS Pharmaceuticals, Inc., and how their positions are changing. At a $8.5M market value, institutional positions materially move CNS Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by CNS Pharmaceuticals, Inc. executives and directors. Shares of CNS Pharmaceuticals, Inc. have traded between $4.93 and $114.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming CNS Pharmaceuticals, Inc.. CNS Pharmaceuticals, Inc. is a $8.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming CNS Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for CNS Pharmaceuticals, Inc.. Coverage tracks CNS Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.